Median Technologies announced that its iBiopsy device has shown superior results in characterising malignant and benign lung nodules in a lung cancer screening (LCS) patient cohort.

The artificial intelligence (AI)-powered iBiopsy Computer Aided Diagnosis (CADx) product works based on a deep learning algorithm on low-dose chest computed tomography.

The study was based on a cohort of 1,696 patients from the National Lung Screening Trial cases (NLST), with a total of 15,608 lung nodules.

iBiopsy CADx has shown an AUC of 0.991, a sensitivity of 95.2%, and a specificity of 95.7% for the characterisation of lung nodules.

Median Technologies said that its iBiopsy CADx has the potential to significantly impact the accuracy, consistency, and adoption of LCS worldwide.

Median founder and CEO Fredrik Brag said: “We have achieved an outstanding performance with our innovative deep learning algorithm for lung nodule characterisation.

“This promising and powerful digital biomarker could have a profound impact on lung cancer screening and help to dramatically reduce the 1.8m lung cancer deaths per year by diagnosing lung cancer patients at a stage that could save their lives.

“Our plan in the coming months is to perform an additional large-scale study for an end-to-end lung cancer screening digital biomarker. Results of this study including both nodule detection (CADe) and characterization (CADx) are expected in Q4 2021.”

The company has launched the iBiopsy Lung Cancer Development programme in February this year, as part of its strategic positioning in early-stage disease diagnosis.

The programme has been supported by the European Investment Bank (EIB) through a financial loan of €35m under the Juncker Plan.

It was also supported by the European Fund for Strategic Investments for research and innovation projects developed by companies with high growth potential.

iBiopsy has been developed based on advanced AI and Data Science technologies and targets the development of AI digital biomarkers for use in several indications.

The platform is currently focused on Lung Cancer, Liver Cancer (HCC) and Liver Disease (NASH).